1Sielecki TM, Boylan JF, Benfield PA, et al. Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation [J]. J Med Chem, 2000, 43, 1-18.
2Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy[J]. Nat Rev Drug Diseov, 2015, 14, 130-146.
3Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase in- hibitor. Mol Cancer Ther, 2010, 9, 2344-2353.
4VanderWel SN, Harvey P J, McNamara D J, et al. Pyrido [ 2,3-d ] pyrimidin-7-ones as specific inhibitors of cyclin- dependent kinase 4. J Med Chem, 2005, 48, 2371-2387.
5Finn RS, Crown JP, Lang I, et al. The eyclin-dependent ki- nase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oneol, 2015, 16, 25-35.
